View Item 

Show simple item record

Spironolactone dose in heart failure with preserved ejection fraction: findings from TOPCAT
dc.contributor.authorFerreira, João Pedro
dc.contributor.authorRossello, Xavier
dc.contributor.authorPocock, Stuart J.
dc.contributor.authorRossignol, Patrick
dc.contributor.authorClaggett, Brian L.
dc.contributor.authorRouleau, Jean‐lucien
dc.contributor.authorSolomon, Scott D.
dc.contributor.authorPitt, Bertram
dc.contributor.authorPfeffer, Marc A.
dc.contributor.authorZannad, Faiez
dc.date.accessioned2020-11-04T16:01:25Z
dc.date.availableWITHHELD_11_MONTHS
dc.date.available2020-11-04T16:01:25Z
dc.date.issued2020-09
dc.identifier.citationFerreira, João Pedro ; Rossello, Xavier; Pocock, Stuart J.; Rossignol, Patrick; Claggett, Brian L.; Rouleau, Jean‐lucien ; Solomon, Scott D.; Pitt, Bertram; Pfeffer, Marc A.; Zannad, Faiez (2020). "Spironolactone dose in heart failure with preserved ejection fraction: findings from TOPCAT." European Journal of Heart Failure 22(9): 1615-1624.
dc.identifier.issn1388-9842
dc.identifier.issn1879-0844
dc.identifier.urihttps://hdl.handle.net/2027.42/163454
dc.publisherJohn Wiley & Sons, Ltd.
dc.subject.otherSpironolactone
dc.subject.otherHeart failure with preserved ejection fraction
dc.subject.otherMean dose
dc.subject.otherDiscontinuation
dc.subject.otherTreatment effect
dc.titleSpironolactone dose in heart failure with preserved ejection fraction: findings from TOPCAT
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelCardiovascular Medicine
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/163454/2/ejhf1909_am.pdfen_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/163454/1/ejhf1909.pdfen_US
dc.identifier.doi10.1002/ejhf.1909
dc.identifier.sourceEuropean Journal of Heart Failure
dc.identifier.citedreferenceBristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N. Carvedilol produces dose- related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 1996; 94: 2807 - 2816.
dc.identifier.citedreferenceTromp J, Ferreira JP, Janwanishstaporn S, Shah M, Greenberg B, Zannad F, Lam CS. Heart failure around the world. Eur J Heart Fail 2019; 21: 1187 - 1196.
dc.identifier.citedreferencePitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709 - 717.
dc.identifier.citedreferencePonikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez- Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016; 18: 891 - 975.
dc.identifier.citedreferenceZannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B; EMPHASIS- HF Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11 - 21.
dc.identifier.citedreferenceFerreira JP, Abreu P, McMurray JJV, van Veldhuisen DJ, Swedberg K, Pocock SJ, Vincent J, Lins K, Rossignol P, Pitt B, Zannad F. Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS- HF trial. Eur J Heart Fail 2019; 21: 345 - 351.
dc.identifier.citedreferenceDesai AS, Liu J, Pfeffer MA, Claggett B, Fleg J, Lewis EF, McKinlay S, O’Meara E, Shah SJ, Sweitzer NK, Solomon S, Pitt B. Incident hyperkalemia, hypokalemia, and clinical outcomes during spironolactone treatment of heart failure with preserved ejection fraction: analysis of the TOPCAT trial. J Card Fail 2018; 24: 313 - 320.
dc.identifier.citedreferenceVaduganathan M, Claggett BL, Chatterjee NA, Anand IS, Sweitzer NK, Fang JC, O’Meara E, Shah SJ, Hegde SM, Desai AS, Lewis EF, Rouleau J, Pitt B, Pfeffer MA, Solomon SD. Sudden death in heart failure with preserved ejection fraction: a competing risks analysis from the TOPCAT trial. JACC Heart Fail 2018; 6: 653 - 661.
dc.identifier.citedreferenceSantema BT, Ouwerkerk W, Tromp J, Sama IE, Ravera A, Regitz- Zagrosek V, Hillege H, Samani NJ, Zannad F, Dickstein K, Lang CC, Cleland JG, Ter Maaten JM, Metra M, Anker SD, van der Harst P, Ng LL, van der Meer P, van Veldhuisen DJ, Meyer S, Lam CS, Voors AA. Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study. Lancet 2019; 394: 1254 - 1263.
dc.identifier.citedreferenceRossignol P, Dobre D, McMurray JJ, Swedberg K, Krum H, van Veldhuisen DJ, Shi H, Messig M, Vincent J, Girerd N, Bakris G, Pitt B, Zannad F. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS- HF). Circ Heart Fail 2014; 7: 51 - 58.
dc.identifier.citedreferenceRossignol P, Ferreira JP. Balancing benefits and risks of spironolactone in HFpEF and chronic kidney disease patients: mind the gap of biological monitoring! JACC Heart Fail 2019; 7: 33 - 35.
dc.identifier.citedreferenceEschalier R, McMurray JJ, Swedberg K, van Veldhuisen DJ, Krum H, Pocock SJ, Shi H, Vincent J, Rossignol P, Zannad F, Pitt B. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS- HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). J Am Coll Cardiol 2013; 62: 1585 - 1593.
dc.identifier.citedreferenceRossignol P, Masson S, Barlera S, Girerd N, Castelnovo A, Zannad F, Clemenza F, Tognoni G, Anand IS, Cohn JN, Anker SD, Tavazzi L, Latini R. Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: insights from the GISSI- HF and Val- HeFT trials. Eur J Heart Fail 2015; 17: 424 - 433.
dc.identifier.citedreferenceStienen S, Ferreira JP, Girerd N, Duarte K, Lamiral Z, McMurray JJV, Pitt B, Dickstein K, Zannad F, Rossignol P. Mean BMI, visit- to- visit BMI variability and BMI changes during follow- up in patients with acute myocardial infarction with systolic dysfunction and/or heart failure: insights from the High- Risk Myocardial Infarction Initiative. Clin Res Cardiol 2019; 108: 1215 - 1225.
dc.identifier.citedreferenceSavarese G, Xu H, Trevisan M, Dahlstrom U, Rossignol P, Pitt B, Lund LH, Carrero JJ. Incidence, predictors, and outcome associations of dyskalemia in heart failure with preserved, mid- range, and reduced ejection fraction. JACC Heart Fail 2019; 7: 65 - 76.
dc.identifier.citedreferenceOlivier A, Pizard A. Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from EMPHASIS- HF trial. Eur J Heart Fail 2017; 19: 1186 - 1197.
dc.identifier.citedreferencePacker M, Poole- Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Ryden L, Thygesen K, Uretsky BF. Comparative effects of low and high doses of the angiotensin- converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999; 100: 2312 - 231 8.
dc.identifier.citedreferenceKonstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, Riegger GA, Malbecq W, Smith RD, Guptha S, Poole- Wilson PA. Effects of high- dose versus low- dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double- blind trial. Lancet 2009; 374: 1840 - 1848.
dc.identifier.citedreferenceClinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison. The NETWORK Investigators. Eur Heart J 1998; 19: 481 - 48 9.
dc.identifier.citedreferenceMarti CN, Fonarow GC, Anker SD, Yancy C, Vaduganathan M, Greene SJ, Ahmed A, Januzzi JL, Gheorghiade M, Filippatos G, Butler J. Medication dosing for heart failure with reduced ejection fraction -  opportunities and challenges. Eur J Heart Fail 2019; 21: 286 - 296.
dc.identifier.citedreferenceLam PH, Dooley DJ, Fonarow GC, Butler J, Bhatt DL, Filippatos GS, Deedwania P, Forman DE, White M, Fletcher RD, Arundel C, Blackman MR, Adamopoulos C, Kanonidis IE, Aban IB, Patel K, Aronow WS, Allman RM, Anker SD, Pitt B, Ahmed A. Similar clinical benefits from below- target and target dose enalapril in patients with heart failure in the SOLVD Treatment trial. Eur J Heart Fail 2018; 20: 359 - 369.
dc.identifier.citedreferenceBeldhuis IE, Myhre PL, Claggett B, Damman K, Fang JC, Lewis EF, O’Meara E, Pitt B, Shah SJ, Voors AA, Pfeffer MA, Solomon SD, Desai AS. Efficacy and safety of spironolactone in patients with HFpEF and chronic kidney disease. JACC Heart Fail 2019; 7: 25 - 32.
dc.identifier.citedreferenceClaggett B, Pocock S, Wei LJ, Pfeffer MA, McMurray JJ, Solomon SD. Comparison of time- to- first event and recurrent- event methods in randomized clinical trials. Circulation 2018; 138: 570 - 577.
dc.identifier.citedreferencePitt B, Anker SD, Bushinsky DA, Kitzman DW, Zannad F, Huang IZ. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double- blind, placebo- controlled study in patients with chronic heart failure (the PEARL- HF) trial. Eur Heart J 2011; 32: 820 - 828.
dc.identifier.citedreferenceZannad F, Ferreira JP, Pitt B. Potassium binders for the prevention of hyperkalaemia in heart failure patients: implementation issues and future developments. Eur Heart J Suppl 2019; 21 (Suppl A): A55 - A60.
dc.identifier.citedreferenceFilippatos G, Anker SD, Bohm M, Gheorghiade M, Kober L, Krum H, Maggioni AP, Ponikowski P, Voors AA, Zannad F, Kim SY, Nowack C, Palombo G, Kolkhof P, Kimmeskamp- Kirschbaum N, Pieper A, Pitt B. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur Heart J 2016; 37: 2105 - 2114.
dc.identifier.citedreferenceFerreira JP, Kraus S, Mitchell S, Perel P, Pineiro D, Chioncel O, Colque R, de Boer RA, Gomez- Mesa JE, Grancelli H, Lam CS, Martinez- Rubio A, McMurray JJ, Mebazaa A, Panjrath G, Pina IL, Sani M, Sim D, Walsh M, Yancy C, Zannad F, Sliwa K. World Heart Federation roadmap for heart failure. Glob Heart 2019; 14: 197 - 214.
dc.identifier.citedreferenceFerreira JP, Mentz RJ, Pizard A, Pitt B, Zannad F. Tailoring mineralocorticoid receptor antagonist therapy in heart failure patients: are we moving towards a personalized approach? Eur J Heart Fail 2017; 19: 974 - 986.
dc.identifier.citedreferenceYancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol 2017; 70: 776 - 803.
dc.identifier.citedreferencePitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O’Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay SM; TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014; 370: 1383 - 1392.
dc.identifier.citedreferencePfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Heitner JF, Lewis EF, O’Meara E, Rouleau JL, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, McKinlay SM, Pitt B. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. Circulation 2015; 131: 34 - 42.
dc.identifier.citedreferencede Denus S, O’Meara E, Desai AS, Claggett B, Lewis EF, Leclair G, Jutras M, Lavoie J, Solomon SD, Pitt B, Pfeffer MA, Rouleau JL. Spironolactone metabolites in TOPCAT -  new insights into regional variation. N Engl J Med 2017; 376: 1690 - 1692.
dc.identifier.citedreferenceFerreira JP, Girerd N, Rossignol P, Zannad F. Geographic differences in heart failure trials. Eur J Heart Fail 2015; 17: 893 - 905.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
ejhf1909.pdf
Size:
1.383MB
Format:
PDF
View/Open
Name:
ejhf1909_am.pdf
Size:
585.9KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.